Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib plus checkpoint inhibitor (CPI) therapy

被引：0
|
作者：
Huynh, L. [1 ]
Du, S. S. [2 ]
Chang, R. [1 ]
Pi, S. [2 ]
Sundaresan, S. [1 ]
Duh, M. S. [1 ]
Thomaidou, D. [3 ]
Zanotti, G. [4 ]
Zakharia, Y. [5 ]
机构：
[1] Anal Grp Inc, Hlth Econ & Outcomes Res, Boston, MA USA
[2] Anal Grp Inc, Hlth Econ & Outcomes Res, New York, NY USA
[3] Pfizer Hellas, Global Med Affairs, Athens, Greece
[4] Pfizer Inc, Oncol HEOR, New York, NY USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75P
引用
收藏
页码：S1404 / S1405
页数：2
相关论文
共 50 条
  • [31] Factors associated with not receiving first-line (1L) immune checkpoint inhibitor (ICI) treatment among patients (pts) with advanced NSCLC and high programmed cell deathligand 1 (PD-L1) expression: An evaluation by age
    Feliciano, J.
    Wu, N.
    Ge, W.
    Quek, R.
    Gleeson, M.
    Jalbert, J. J.
    Hsu, M. L.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1075 - S1075
  • [32] Treatment (tx) patterns of patients with advanced renal cell carcinoma (aRCC) receiving first-line (1L) tx: Results from a cross-sectional real-world study
    Zanotti, G.
    Kim, R.
    Krulewicz, S. P.
    Hall, J. P.
    Leith, A.
    Bailey, A.
    Liu, F.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Pembrolizumab plus axitinib (P plus A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status - a network meta-analysis (NMA)
    McGovern, Ian
    Shirali, Rohan
    Simon, Andrew
    Zhong, Yichen
    Perini, Rodolfo
    Lorenzi, Maria
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
    Htut, T. Win
    Swarup, S.
    Sultan, A.
    Mogollon-Duffo, F.
    Meda, S.
    Arevalo, M.
    Adhikari, N.
    Naing, P. T.
    Hlaing, P. P.
    Myat, Y. Mon
    Hardwicke, F.
    D'Cunha, N.
    Tijani, L.
    Thein, K. Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 527 - 527
  • [35] Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
    Rane, Pratik
    Yan, Kevin
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 421 - 421
  • [36] Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.
    Grivas, Petros
    Laliberte, Francois
    Doleh, Yunes
    O'Connor, Cristi
    Duh, Mei Sheng
    Shenolikar, Rahul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
    Voss, M. H.
    Garmezy, B.
    Kim, S. H.
    Rey, J. P. Maroto
    Mansinho, A. B.
    Rodriguez-Vida, A.
    Oliveira, J.
    van Dongen, M.
    Rodriguez, L. Medina
    Negrier, S.
    Tran, B.
    Carneiro, B. A.
    Alvarez, E. Castanon
    Rha, S. Y.
    Wang, Y.
    Gainer, S. D.
    Tang, Z.
    Achour, I.
    Asare, J. M.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1012 - S1012
  • [38] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
    Albiges, L.
    Rini, B. I.
    Haanen, J. B. A. G.
    Motzer, R. J.
    Kollmannsberger, C. K.
    Negrier, S.
    Nole, F.
    Bedke, J.
    Bilen, M. A.
    Nathan, P.
    Tomita, Y.
    Huang, B.
    Ching, K. A.
    Chudnovsky, A.
    Robbins, P. B.
    di Pietro, A.
    Thomaidou, D.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem Airatovich
    Hawkins, Robert E.
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [40] MULTIDIMENSIONAL TREATMENT EFFECT NETWORK META-ANALYSIS TO ESTIMATE SURVIVAL OF THERAPIES FOR PATIENTS WITH FIRST-LINE (1L) ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) IN FRANCE
    Gittfried, A. M., V
    Lambton, M.
    Nickel, K.
    May, J. R.
    Branchoux, S.
    Kroep, S.
    VALUE IN HEALTH, 2022, 25 (01) : S25 - S25
12345